Alpha Beta Pharma

Alpha Beta Therapeutics is developing fully humanized antibodies to potentiate immune destruction of cancer by arming tumor-associated macrophages. Their lead program involves PGG-glucan, which has reached Phase 3 clinical trials for colorectal cancer. Another preclinical program targets integrin αvβ3 to address drug-resistant cancers and enhance standard-of-care therapies across multiple solid tumors including lung, pancreas, colon, breast, brain, and kidney cancers. The company’s approach leverages ADCC mechanisms to selectively engage tumor-localized effector cells and overcome resistance mechanisms such as epithelial-to-mesenchymal transition.